PMID- 35598638
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20220726
IS  - 2213-3941 (Electronic)
IS  - 0003-4266 (Linking)
VI  - 83
IP  - 4
DP  - 2022 Aug
TI  - Calcium homeostasis and hyperparathyroidism: Nephrologic and endocrinologic 
      points of view.
PG  - 237-243
LID - S0003-4266(22)00083-X [pii]
LID - 10.1016/j.ando.2022.05.003 [doi]
AB  - Parathyroid hormone (PTH) is a hypercalcemic hormone acting on kidneys, bone and 
      intestine. PTH promotes calcium release from the bone, renal calcium reabsorption 
      and phosphate excretion, and conversion of 25-hydroxyvitamin D to 
      1,25-dihydroxyvitamin D-3. Hyperparathyroidism consists in PTH elevation, which 
      may be adapted (secondary hyperparathyroidism) or non-adapted to calcemia levels 
      (primary hyperparathyroidism, familial hypercalcemia/hypocalciuria, tertiary 
      hyperparathyroidism). Primary hyperparathyroidism (PHP) features hypercalcemia 
      and elevated or inappropriate PTH elevation. PHP may be revealed by biological 
      abnormalities such as hypercalcemia and can be accompanied by renal complications 
      (hypercalciuria, nephrolithiasis, nephrocalcinosis) and/or osteoporosis. However, 
      it can also be normocalcemic and calcium loading will be necessary to diagnosis 
      it. The differential diagnosis of PHP is familial hypocalciuric hypercalcemia 
      (FHH), a dominant autosomal disease implicating a calcium sensing 
      receptor-inactivating mutation. It impairs parathyroid cell sensitivity to 
      calcemia elevation and thus induces excessive PTH stimulation, leading to 
      hypercalcemia. Secondary HP (SHP) consists in PTH elevation secondary to a 
      stimulus that needs to be corrected. 25 OHvitD deficiency, kidney failure, renal 
      hypercalciuria, malabsorption and some drugs can induce SHP. Tertiary HP (THP) 
      consists in autonomous PTH secretion by the parathyroid glands after prolonged 
      stimulation under SHP, of whatever cause. This parathyroid autonomy results from 
      the polyclonal hyperplasia observed in SHP progressing toward monoclonal nodular 
      proliferation, leading to nodular hyperplasia or parathyroid adenoma (or, 
      exceptionally, carcinoma), with reduced expression of CaSR and vitamin D 
      receptor. In patients under dialysis, the frontier between SHP and THP is a 
      matter of debate. This review will focus on the pathophysiology of calcium, 
      diagnosis, and management of hyperparathyroidism.
CI  - Copyright (c) 2022 Elsevier Masson SAS. All rights reserved.
FAU - Lemoine, Sandrine
AU  - Lemoine S
AD  - Service de nephrologie et d'exploration fonctionnelle renale, hopital 
      Edouard-Herriot, hospices civils de Lyon, Lyon, France; Universite Lyon 1, Lyon, 
      France; Centre de reference des maladies rares du calcium et du phosphore, Centre 
      de reference des maladies renales rares, filieres de sante maladies rares OSCAR, 
      ORKID et ERKNet, Lyon, France. Electronic address: 
      sandrine.lemoine01@chu-lyon.fr.
FAU - Figueres, Lucile
AU  - Figueres L
AD  - Universite de Nantes, Quai de Tourville, 44000 Nantes, France; Institut de 
      transplantation urologie nephrologie (ITUN), CHU Nantes, 30, boulevard 
      Jean-Monnet, 44093 Nantes cedex, France.
FAU - Bacchetta, Justine
AU  - Bacchetta J
AD  - Centre de reference des maladies rares du calcium et du phosphore, Centre de 
      reference des maladies renales rares, filieres de sante maladies rares OSCAR, 
      ORKID et ERKNet, Lyon, France; Service de nephrologie rhumatologie et 
      dermatologie pediatriques, hopital Femme-Mere-Enfant, Bron, France; Inserm 1033, 
      prevention des maladies osseuses, Lyon, France.
FAU - Frey, Samuel
AU  - Frey S
AD  - Universite de Nantes, Quai de Tourville, 44000 Nantes, France; Chirurgie 
      cancerologique, digestive et endocrinienne, Institut des maladies de l'appareil 
      digestif, Hotel-Dieu, CHU Nantes, Nantes, France.
FAU - Dubourg, Laurence
AU  - Dubourg L
AD  - Service de nephrologie et d'exploration fonctionnelle renale, hopital 
      Edouard-Herriot, hospices civils de Lyon, Lyon, France; Universite Lyon 1, Lyon, 
      France; Centre de reference des maladies rares du calcium et du phosphore, Centre 
      de reference des maladies renales rares, filieres de sante maladies rares OSCAR, 
      ORKID et ERKNet, Lyon, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220519
PL  - France
TA  - Ann Endocrinol (Paris)
JT  - Annales d'endocrinologie
JID - 0116744
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Parathyroid Hormone)
RN  - 0 (Receptors, Calcium-Sensing)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - *Bone Density Conservation Agents
MH  - Calcium/metabolism
MH  - Homeostasis
MH  - Humans
MH  - *Hypercalcemia/diagnosis/etiology
MH  - Hypercalciuria
MH  - *Hyperparathyroidism, Primary/complications/diagnosis
MH  - Hyperplasia
MH  - Parathyroid Hormone
MH  - Receptors, Calcium-Sensing/genetics
OTO - NOTNLM
OT  - Calcemia
OT  - Calcium sensing receptor
OT  - Familial hypocalciuric hypercalcemia
OT  - Hyperparathyroidism
OT  - Parathyroid hormone
EDAT- 2022/05/23 06:00
MHDA- 2022/07/27 06:00
CRDT- 2022/05/22 19:23
PHST- 2022/05/23 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
PHST- 2022/05/22 19:23 [entrez]
AID - S0003-4266(22)00083-X [pii]
AID - 10.1016/j.ando.2022.05.003 [doi]
PST - ppublish
SO  - Ann Endocrinol (Paris). 2022 Aug;83(4):237-243. doi: 10.1016/j.ando.2022.05.003. 
      Epub 2022 May 19.